Advertisement

Comparative Clinical Pathology

, Volume 27, Issue 5, pp 1133–1140 | Cite as

Estimation of telomerase, AFP, and AFP-L3 levels in Sudanese patients with hepatocellular carcinoma and chronic liver diseases

  • Fayza A. Rahamtalla
  • Mohammed S. M. Abdalla
  • Salma B. M. Mudawi
  • Mohammed A. H. Kheir Elsid
  • Iman M. Shammat
Original Article
  • 21 Downloads

Abstract

Telomerase enzyme activity is considered a widespread and relatively selective tumor cell marker feature that can be used for detecting the presence of various neoplastic cells. The positive activity of telomerase enzyme was also recorded in chronic liver disease and is evaluated as a more appropriate biomarker for differentiating hepatocellular carcinoma (HCC) from chronic liver diseases. The current study aimed to evaluate telomerase, AFP, and AFP-L3 levels in Sudanese patients with hepatocellular carcinoma and chronic liver diseases. The study enrolled 113 patients: HCC (n = 33), cirrhosis (n = 33), and chronic hepatitis (n = 47), jointly with 50 healthy controls. Enzyme-linked immunosorbent assay (ELISA) technique was used to estimate the telomerase, AFP, and AFP-L3 levels in blood samples. The telomerase level was elevated in 70% of HCC patients, and it was significantly higher in HCC patients compared to that in healthy controls (1.38 versus 0.35 ng/ml, respectively; P < 0.01). Serum alpha-fetoprotein (AFP) and Lens culinaris agglutinin-reactive (AFP-L3) levels were also significantly elevated in HCC patients compared to healthy controls (130.76 versus 5.59 ng/ml; P < 0.01) and (59.76 versus 0.49 ng/ml; P < 0.01), respectively. The combination between telomerase and AFP or AFPL-3 lead to increased telomerase sensitivity (85 and 79%, respectively).Telomerase was found to be further sensitive in patients with a tumor size of less than 5 cm as well as to tumors of more than 5 cm. Two healthy control samples showed an increase in telomerase level. The combined use of telomerase, AFP, and AFP-L3 levels might be useful for achieving better sensitivity for HCC patients.

Keywords

Hepatocellular carcinoma ELISA telomerase cirrhosis Chronic hepatitis 

Notes

Acknowledgements

Special thanks to Dr. Abdelbagi Ahmed for helping with the statistical analysis. We are grateful to the director and staff of Molecular Biology Laboratory, Faculty of Medical Laboratory Sciences, Alneelain University, for providing lab facilities.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Compliance with ethical standards

Ethical approval

All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all4966 individual participants included in the study.

References

  1. Abdel Hady A, El Shanawany F, Hassan MM, Anas A, Mostafa I, Abdel Hadi A (2010) Evaluation of human telomerase activity as a novel tumor marker for hepatocellular carcinoma. Life Sci J 7(4):153–161Google Scholar
  2. American Federation for Aging Research (AFAR) (2011) Info-aging Guide to Telomeres and Telomerase. New York, Biol Aging 1–7Google Scholar
  3. Belair CD, Yeager TR, Lopez PM, Reznikoff CA (1997) Telomerase activity: a biomarker of cell proliferation, not malignant transformation. Proc Natl Acad Sci U S A 94(25):13677–11368CrossRefPubMedPubMedCentralGoogle Scholar
  4. Bosch FX, Ribes J, Cléries R, Díaz M (2005) Epidemiology of hepatocellular carcinoma. Clin Liver Dis 9(2):191–211CrossRefPubMedGoogle Scholar
  5. Bruix J, Sherman M (2011) American Association for the Study of Liver Diseases: management of hepatocellular carcinoma: an update. Hepatology 53(3):1020–1022CrossRefPubMedPubMedCentralGoogle Scholar
  6. Choi JY, Jung SW, Kim HY, Kim M, Kim Y, Kim DG, Oh EJ (2013) Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AF. World J Gastroenterol 19(3):339–346CrossRefPubMedPubMedCentralGoogle Scholar
  7. Durant ST (2012) Telomerase-independent paths to immortality in predictable cancer subtype. J Cancer 3:67–82CrossRefPubMedPubMedCentralGoogle Scholar
  8. El-Garem H, Khayyal AA, Mosa TE, Ramadan A (2010) Telomerase activity in hepatocellular carcinoma and chronic hepatitis C virus. J Genet Eng Biotechnol 8(1):81–87Google Scholar
  9. Emad IA, Samir MA, Emad EFI, Mohamad TM, Taher IES (2002) Assaying telomerase activity in three different malignant condition in Egyptian patients employing the polymerase chain reaction technique. J Egypt Nat Cancer Inst 14(3):229–236Google Scholar
  10. Episkopou H, Draskovic I, Van Beneden A, Tilman G, Mattiussi M, Gobin M et al (2014) Alternative lengthening of telomeres is characterized by reduced compaction of telomeric chromatin. Nucleic Acids Res 42(7):4391–4405CrossRefPubMedPubMedCentralGoogle Scholar
  11. Farinati F, Marino D, De Giorgio M, Baldan A, Cantarini M, Cursaro C, Rapaccini G, Del Poggio P, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Bernardi M, Trevisani F (2006) Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol 101(3):524–532CrossRefPubMedGoogle Scholar
  12. Gomaa AI, Khan SA, Edward LS (2009) Diagnosis of hepatocellular carcinoma. World J Gastroenterol 15(11):1301–1314CrossRefPubMedPubMedCentralGoogle Scholar
  13. Hassan EG, Hanan AH, Ahmed F, Wafaa AA, Mohey EA, Mona S et al (2013) Tissue biomarkers in the early detection of hepatocellular carcinoma among Egyptian patients with chronic hepatitis C: a possible genetic profile. Br J Med Med Res 3(4):1858–1870CrossRefGoogle Scholar
  14. Heaphy CM, Subhawong AP, Hong SM, Goggins MG, Montgomery EA, Gabrielson E, Netto GJ, Epstein JI, Lotan TL, Westra WH, Shih IM, Iacobuzio-Donahue CA, Maitra A, Li QK, Eberhart CG, Taube JM, Rakheja D, Kurman RJ, Wu TC, Roden RB, Argani P, de Marzo AM, Terracciano L, Torbenson M, Meeker AK (2011) Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol 179(4):1608–1615CrossRefPubMedPubMedCentralGoogle Scholar
  15. Hiyama E, Hiyama K (2002) Clinical utility of telomerase in cancer. Oncogene 21(4):643–649CrossRefPubMedGoogle Scholar
  16. Huang FC, Chang CC, Lou PJ, Kuo IC, Chien CW, Chen CT, Shieh FY, Chang TC, Lin JJ (2008) G-quadruplex stabilizer 3,6-bis (1-methyl-4-vinylpyridinium) carbazolediiodide induces accelerated senescence and inhibits tumorigenic properties in cancer cells. Mol Cancer Res 6(6):955–964CrossRefPubMedGoogle Scholar
  17. Huang YK, Fan XG, Qiu F, Wang ZM (2013) Combined detection of mRNA expression of alpha-fetoprotein in peripheral blood and telomerase activity of monocytes in hepatocellular carcinoma patients. Hepato-Gastroenterology 60(121):1–5PubMedGoogle Scholar
  18. Ibrahim FF, Sayed MM, El-garem HA, Ghannam MM (2008) Blood telomerase activity and DNA dielectric properties in human hepatocellular carcinoma and chronic liver disease. Biotechnology 7(1):66–72CrossRefGoogle Scholar
  19. Ishikawa F (1997) Telomere crisis, the driving force in cancer cell evolution. BiochemBiophys Res Commun 230(1):1–6CrossRefGoogle Scholar
  20. Jäger K, Walter M (2016) Therapeutic targeting of telomerase. Genes (Basel) 7(7):39CrossRefPubMedCentralGoogle Scholar
  21. Jakupciak JP, Wang W, Barker PE, Srivastava S, Atha DH (2004) Analytical validation of telomerase activity for cancer early detection. J Mol Diagn 6(3):157–165CrossRefPubMedPubMedCentralGoogle Scholar
  22. Johnson PJ, Pirrie SJ, Cox TF, Berhane S, Teng M, Palmer D, Morse J, Hull D, Patman G, Kagebayashi C, Hussain S, Graham J, Reeves H, Satomura S (2014) The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiol Biomark Prev 23(1):144–153CrossRefGoogle Scholar
  23. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW (1994) Specific association of human telomerase activity with immortal cells and cancer. Science 266(5193):2011–2015CrossRefPubMedGoogle Scholar
  24. Kobayashi S, Tomokuni A, Takahashi H, Akita H, Sugimura K, Miyoshi N, Moon JH, Yasui M, Omori T, Ohue M, Fujiwara Y, Yano M, Sakon M (2016) The clinical significance of alpha-fetoprotein mRNAs in patients with hepatocellular carcinoma. Gastrointest Tumors 3:141–152CrossRefGoogle Scholar
  25. Kojima H, Yokosuka O, Imazeki F, Saisho H, Omata M (1997) Telomerase activity and telomere length in hepatocellular carcinoma and chronic liver disease. Gastroenterology 112(2):493–500CrossRefPubMedGoogle Scholar
  26. Lechel A, Manns MP, Rudolph KL (2004) Telomeres and telomerase: new targets for the treatment of liver cirrhosis and hepatocellular carcinoma. J Hepatol 41(3):491–497CrossRefPubMedGoogle Scholar
  27. Llovet JM, Bruix J (2008) Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 48(Suppl 1):20–37CrossRefGoogle Scholar
  28. Malaguarnera G, Giordano M, Paladina I, Berretta M, Cappellani A, Malaguarnera M (2010) Serum markers of hepatocellular carcinoma. Dig Dis Sci 55(10):2744–2755CrossRefPubMedGoogle Scholar
  29. Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, Reddy KR, Harnois D, Llovet JM, Normolle D, Dalhgren J, Chia D, Lok AS, Wagner PD, Srivastava S, Schwartz M (2009) Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 137(1):110–118CrossRefPubMedPubMedCentralGoogle Scholar
  30. Miura N, Maruyama S, Oyama K, Horie Y, Kohno M, Noma E, Sakaguchi S, Nagashima M, Kudo M, Kishimoto Y, Kawasaki H, Hasegawa J, Shiota G (2007) Development of a novel assay to quantify serum human telomerase reverse transcriptase messenger RNA and its significance as a tumor marker for hepatocellular carcinoma. Oncology 72(1):45–51CrossRefPubMedGoogle Scholar
  31. Molenaar C, Wiesmeijer K, Verwoerd N, Khazen S, Eils R, Tanke H, Dirks RW (2003) Visualizing telomere dynamics in living mammalian cells using PNA probes. EMBO J 22(24):6631–6641CrossRefPubMedPubMedCentralGoogle Scholar
  32. Murnane JP, Sabatier L (2004) Chromosome rearrangements resulting from telomere dysfunction and their role in cancer. BioEssays 26(11):1164–1174CrossRefPubMedGoogle Scholar
  33. Nouso K, Urabe Y, Higashi T, Nakatsukasa H, Hino N, Ashida K, Kinugasa N, Yoshida K, Uematsu S, Tsuji T (1996) Telomerase as a tool for the differential diagnosis of human hepatocellular carcinoma. Cancer 78(2):232–236CrossRefPubMedGoogle Scholar
  34. Omer R, Van’t Veer P, Kadaru AM, Kampman E, El Khidir IM, Fedail SS et al (2001) The role of hepatitis B and hepatitis C viral infections in the incidence of hepatocellular carcinoma in Sudan. Trans R Soc Trop Med Hyg 95(5):487–491CrossRefPubMedGoogle Scholar
  35. Ozen M, Imam SA, Datar RH, Multani AS, Narayanan R, Chung LW et al (1998) Telomeric DNA: marker for human prostate cancer development? Prostate 36(4):264–271CrossRefPubMedGoogle Scholar
  36. Park YM, Choi JY, Byun BH, Cho CH, Kim HS, Kim BS (1998) Telomerase is strongly activated in hepatocellular carcinoma but not in chronic hepatitis and cirrhosis. Exp Mol Med 30(1):35–40CrossRefPubMedGoogle Scholar
  37. Pathak S, Risin S, Brown N, Berry K (1994) Telomeric association of chromosomes is an early manifestation of programmed cell-death.Int. J Oncol 4(2):323–328Google Scholar
  38. Satra M, Gatselis N, Iliopoulos D, Zacharoulis D, Dalekos GN, Tsezou A (2007) Real-time quantification of human telomerase reverse transcriptase mRNA in liver tissues from patients with hepatocellular cancer and chronic viral hepatitis (2007). J Viral Hepat 14(1):41–47CrossRefPubMedGoogle Scholar
  39. Shata YM, Mudawi S, Fedail SS, Al Abd BH, Ismaeil AM, Ahmed SM (2014) Assessment of Lens culinaris agglutinin-reactive fraction of alpha fetoprotein as an early diagnostic marker for hepatocellular carcinoma among Sudanese patients with chronic liver disease. Cancer Oncol Res 2(1):1–6Google Scholar
  40. Shay JW, Gazdar AF (1997) Telomerase in the early detection of cancer. J Clin Pathol 50:106–109CrossRefPubMedPubMedCentralGoogle Scholar
  41. Stefaniuk P, Cianciara J, Wiercinska-Drapalo A (2010) Present and future possibilities for early diagnosis of hepatocellular carcinoma. World J Gastroenterol 16(4):418–424CrossRefPubMedPubMedCentralGoogle Scholar
  42. Tahara H, Nakanishi T, Kitamoto M, Nakashio R, Shay JW, Tahara E, Kajiyama G, Ide T (1995) Telomerase activity in human liver tissues: comparison between chronic liver disease and hepatocellular carcinomas. Cancer Res 55(13):2734–2736PubMedGoogle Scholar
  43. Tateishi R, Haruhiko Y, Yutaka M, Norio M, Yuji K, Masao O (2008) Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review. Hepatol Int 2(1):17–30CrossRefPubMedGoogle Scholar
  44. Tahtouh R, Azzi AS, Alaaeddine N, Chamat S, Bouharoun-Tayoun H, Wardi L et al (2015) Telomerase inhibition decreases alpha-fetoprotein expression and secretion by hepatocellular carcinoma cell lines: in vitro and in vivo study. PLoS One 10(10):e0119512.  https://doi.org/10.1371/journal.pone.0119512 CrossRefPubMedPubMedCentralGoogle Scholar
  45. Toyoda H, Kumada T, Tada T, Sone Y, Kaneoka Y, Maeda A (2015) Tumor markers for hepatocellular carcinoma: simple and significant predictors of outcome in patients with HCC. Liver Cancer 4(2):126–136CrossRefPubMedPubMedCentralGoogle Scholar
  46. Wang L, Yao M, Dong Z, Zhang Y, Yao D (2014) Circulating specific biomarkers in diagnosis of hepatocellular carcinoma and its metastasis monitoring. Tumour Biol 35(1):9–20CrossRefPubMedGoogle Scholar
  47. Wu W, Yao DF, Qiu LW, Wu XH, Yao M, Su XQ, Zou L (2005) Abnormal expression of hepatomas and circulating telomerase and its clinical values. Hepatobiliary Pancreat Dis Int 4(4):544–549PubMedGoogle Scholar
  48. Yao DF, Dong ZZ, Yao M (2007) Specific molecular markers in HCC. Hepatobiliary Pancreat Dis Int 6(3):15–22Google Scholar
  49. Yao DF, Wu W, Yao M, Qiu LW, Wu XH, Su XQ et al (2006) Dynamic alteration of telomeraseexpression and its diagnostic significance in liver or peripheral blood for hepatocellular carcinoma. World J Gastroenterol 12(31):4966–4972Google Scholar
  50. Zhou L, Jia L, Feng L (2006) Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol 12(8):1175–1181CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag London Ltd., part of Springer Nature 2018

Authors and Affiliations

  • Fayza A. Rahamtalla
    • 1
  • Mohammed S. M. Abdalla
    • 2
  • Salma B. M. Mudawi
    • 3
  • Mohammed A. H. Kheir Elsid
    • 4
  • Iman M. Shammat
    • 5
  1. 1.Faculty of Medical Laboratory SciencesOmdurman Islamic UniversityKhartoumSudan
  2. 2.Atomic Energy Commission (SAEC)KhartoumSudan
  3. 3.National Center for GI and Liver DiseaseIbnSina HospitalKhartoumSudan
  4. 4.Faculty of MedicineOmdurman IslamicKhartoumSudan
  5. 5.Biology Department, Faculty of ScienceTaibah UniversityMadinahSaudi Arabia

Personalised recommendations